Drug Trial Radar · NCT05326412
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
May 19, 2022
Primary completion
Mar 5, 2025
Study completion Jul 25, 2025
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Apr 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was an exploratory, two-part, 12-week, Phase 2a study evaluated the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years. This study consisted of participants who had been on a standard-of-care (SoC) mono (long-acting β2-agonist \[LABA\]) or long-acting muscarinic antagonist \[LAMA\]), double (inhaled corticosteroid \[ICS\] + LABA, LABA + LAMA or ICS + LAMA), or triple (ICS + LABA + LAMA) controller therapy for COPD for at least 3 months prior to Screening (Visit 1) with stable dose and regimen for controller therapy for ≥1 month prior to Screening (Visit 1) and during the screening period. Participants would stay on their established controller medications for COPD throughout the duration of the study, with the exception of systemic corticosteroids and/or antibiotics used for acute exacerbation of COPD (AECOPD). Part A would consist of participants who were former smokers with COPD; Part B would consist of participants who were current smokers with COPD. The total study duration for each part (Part A and Part B) was approximately 36 weeks: * 4-week screening period * 12-week treatment period * 20-week followup period
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab SAR440340Drug
Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Endobronchial Biopsies in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12Time frame: Baseline (Week 0) and Week 12
- Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Bronchial Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12Time frame: Baseline (Week 0) and Week 12
- Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Nasal Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12Time frame: Baseline (Week 0) and Week 12
Locations
23 sites in 7 countries. Site status is shown where the registry gives one.
UCLA Medical Center - Harbor- Site Number : 8400006
Torrance, California
National Jewish Health Medical Center- Site Number : 8400012
Denver, Colorado
University of Miami UHealth Tower- Site Number : 8400015
Miami, Florida
University of Kansas Medical Center- Site Number : 8400004
Kansas City, Missouri
Allergy, Asthma and Clinical Research- Site Number : 8400010
Oklahoma City, Oklahoma
Clinical Research Associates of Central PA - Dubois- Site Number : 8400011
DuBois, Pennsylvania
University of Texas - Southwestern Medical Center- Site Number : 8400014
Dallas, Texas
Investigational Site Number : 0560001
Edegem, Belgium
Hospital Beneficência Portuguesa de São Paulo- Site Number : 0760005
São Paulo, Brazil
Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760003
Porto Alegre, Rio Grande do Sul, Brazil
Hospital e Maternidade Celso Pierro - PUC-Campinas- Site Number : 0760004
Campinas, São Paulo, Brazil
Integral Pesquisa e Ensino- Site Number : 0760006
Votuporanga, São Paulo, Brazil
Investigational Site Number : 2080003
Aalborg, Denmark
Investigational Site Number : 2080001
Copenhagen, Denmark
Investigational Site Number : 2080002
Hvidovre, Denmark
Investigational Site Number : 2760005
Freiburg im Breisgau, Germany
Investigational Site Number : 2760001
Großhansdorf, Germany
Investigational Site Number : 2760004
Peine, Germany
Investigational Site Number : 5280001
Groningen, Netherlands
Investigational Site Number : 8260002
Liverpool, United Kingdom
Investigational Site Number : 8260003
Wythenshawe, Cheshire West And Chester, United Kingdom
Investigational Site Number : 8260004
London, London, City of, United Kingdom
Investigational Site Number : 8260001
Nottingham, Nottinghamshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.